15 Years of penile cancer management in the United States: An analysis of the use of partial penectomy for localized disease and chemotherapy in the metastatic setting

2016 ◽  
Vol 34 (12) ◽  
pp. 530.e1-530.e7 ◽  
Author(s):  
Matthew Mossanen ◽  
Sarah Holt ◽  
John L. Gore ◽  
Daniel W. Lin ◽  
Jonathan L. Wright
Urology ◽  
2016 ◽  
Vol 90 ◽  
pp. 82-88 ◽  
Author(s):  
Richard S. Matulewicz ◽  
Andrew S. Flum ◽  
Irene Helenowski ◽  
Borko Jovanovic ◽  
Bryan Palis ◽  
...  

2012 ◽  
Vol 38 (6) ◽  
pp. 728-738 ◽  
Author(s):  
Vivian Colón-López ◽  
Ana P. Ortiz ◽  
Marievelisse Soto-Salgado ◽  
Mariela Torres-Cintrón ◽  
Curtis A. Pettaway ◽  
...  

2013 ◽  
Vol 49 (6) ◽  
pp. 1414-1421 ◽  
Author(s):  
R.H.A. Verhoeven ◽  
M.L.G. Janssen-Heijnen ◽  
K.U. Saum ◽  
R. Zanetti ◽  
A. Caldarella ◽  
...  

Author(s):  
Daniel H. Ahn ◽  
Andrew H. Ko ◽  
Neal J. Meropol ◽  
Tanios S. Bekaii-Saab

Pancreatic cancer remains the fourth leading cause of cancer deaths in the United States with a dismal prognosis and a 5-year survival of less than 5% across all stages.1In 2014, there were approximately 46,420 new cases of pancreatic cancer with only 9% of patients having localized disease.2Given that the vast majority of patients present with advanced disease, much of the focus for drug development has been in the metastatic setting, which is evident with the advent of two combination chemotherapy regimens for this indication. Although conventional cytotoxic chemotherapy remains the standard of care, an ongoing search for novel therapeutic approaches continues. We will highlight several new approaches here, with a particular emphasis on immunotherapeutic strategies. We will also introduce concepts regarding the potential economic effects associated with the development and implementation of new treatments in pancreatic cancer.


2004 ◽  
Vol 2 (1) ◽  
pp. 5-11
Author(s):  
Matthew R. Cooperberg ◽  
Jeanette M. Broering ◽  
David M. Latini ◽  
Mark S. Litwin ◽  
Katrine L. Wallace ◽  
...  

1994 ◽  
Vol 12 (8) ◽  
pp. 1718-1723 ◽  
Author(s):  
R W Frelick

PURPOSE To review the growth of community physicians' involvement in National Cancer Institute (NCI) clinical research trials as a significant contribution to cancer control, and to show their impact, not yet fully realized, on cancer morbidity and mortality in the United States. DESIGN Background information, based on the personal experience of participants, as well as a review of pertinent literature, portrays the evolution of the clinical research component of community oncology in the United States over the last 25 years. RESULTS Data from Community Clinical Oncology Programs (CCOPs) I and II have been used to outline some of the results of this far-reaching program. CONCLUSION The CCOP was introduced at an appropriate time to expand the clinical trial resources of the NCI, while at the same time helping community oncologists practice state-of-the-art cancer management found in the research protocols. This in turn provided improved resources to manage cancer patients, as most of them are treated in their own communities. CCOPs have also indirectly had a positive impact on the trial processes of the NCI cooperative groups and comprehensive cancer centers, and have helped to widen the scope and hasten progress in cancer-control research and practice.


2020 ◽  
Author(s):  
Xiaohong Su ◽  
Kaihui Wu ◽  
Shuo Wang ◽  
Bingkun Li ◽  
Chuanyin Li ◽  
...  

Abstract Purpose: Penile cancer (PC) is an uncommon malignancy in the urinary system of males. The present study aims to compare survival outcomes of PC patients among racial/ethnic groups in the United States. Methods and materials: Patients with PC were identified in the Surveillance, Epidemiology, and End Results (SEER) registries from 2004 to 2015. The SEER database represents 28% of the U.S. population. Race/ethnicity was categorized as non-hispanic white (NHW), hispanic white (HW), black, Asian/Pacific Islander (A/PI), or American Indian/Alaskan native (AI/AN). Kaplan-Meier method with the log-rank test was used to assess cancer-specific survival (CSS) and overall survival (OS). Multivariate analysis was conducted using Cox’s proportional hazard model. Results: A total of 3955 patients with PC were included. There were significant differences in age, marital status, tumor location, histology, grade, lymphadenectomy, and radiotherapy according to race/ethnicity. Univariate analysis revealed that A/PIs were significantly associated with better CSS (p= 0.005) and OS (p= 0.025) for most subtypes. The 5-year CSS rates for NHWs, HWs, blacks, A/PIs and AI/ANs were 79.4%, 74.2%, 75.9%, 87.1%, and 78.9%, respectively. The 5-year OS rates for NHWs, HWs, blacks, A/PIs and AI/ANs were 63.4%, 64.1%, 60.5%, 73.0%, and 70.9%, respectively. After adjusting for other factors, racial disparity was an independent risk factor for CSS and OS in the multivariate analysis (p=0.010 and p=0.017, respectively). Conclusions: Our results suggested that racial differences existed among PC patients in the United States with respect to patient clinicopathological features and survival. Long-term survival disparities were evident in PC patients, that the survival of NHWs, HWs, and blacks was worse than that of A/PIs.


Sign in / Sign up

Export Citation Format

Share Document